Morgan Stanley
ELTX icon

Morgan Stanley’s Elicio Therapeutics ELTX Stock Holding History

Morgan Stanley’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$720K Buy
395,833
+370,287
+1,449% +$1.03M ﹤0.01% 5437
2026
Q2 		$100K Sell
25,546
-6,858
-21% -$68.9K ﹤0.01% 6252
2026
Q1 		$346K Buy
32,404
+17,851
+123% +$172K ﹤0.01% 5649
2025
Q4 		$116K Buy
14,553
+13,017
+847% +$118K ﹤0.01% 6128
2025
Q3 		$16.8K Buy
1,536
+1,156
+304% +$11.7K ﹤0.01% 6746
2025
Q2 		$2.93K Sell
380
-462
-55% -$2.87K ﹤0.01% 7150
2025
Q1 		$5.19K Buy
842
+612
+266% +$4.74K ﹤0.01% 6980
2024
Q4 		$1.17K Sell
230
-10
-4% -$49 ﹤0.01% 7250
2024
Q3 		$1.21K Buy
240
+10
+4% +$44 ﹤0.01% 7203
2024
Q2 		$945 Buy
230
+100
+77% +$846 ﹤0.01% 7161
2024
Q1 		$988 Sell
130
-27
-17% -$135 ﹤0.01% 7173
2023
Q4 		$1.31K Hold
157
– – ﹤0.01% 7103
2023
Q3 		$1.33K Buy
157
+30
+24% +$286 ﹤0.01% 7196
2023
Q2 		$1.21K Sell
127
-285
-69% -$2.61K ﹤0.01% 7273
2023
Q1 		$2.39K Sell
412
-67
-14% -$447 ﹤0.01% 7204
2022
Q4 		$3.88K Sell
479
-161
-25% -$1.46K ﹤0.01% 7215
2022
Q3 		$5K Sell
640
-1,086
-63% -$11.3K ﹤0.01% 7246
2022
Q2 		$20K Sell
1,726
-10,797
-86% -$172K ﹤0.01% 6986
2022
Q1 		$266K Sell
12,523
-3,600
-22% -$81.3K ﹤0.01% 5764
2021
Q4 		$468K Buy
16,123
+12,178
+309% +$616K ﹤0.01% 5594
2021
Q3 		$385K Buy
3,945
+1,205
+44% +$130K ﹤0.01% 5651
2021
Q2 		$357K Buy
2,740
+2,645
+2,784% +$382K ﹤0.01% 5720
2021
Q1 		$17K Buy
+95
New +$18.3K ﹤0.01% 6776

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Morgan Stanley's ELTX Position: Q3 2026 in Review

Morgan Stanley increased its Elicio Therapeutics (ELTX) stake by 1,449% in Q3 2026, buying an estimated $1.03M and bringing the position to 395,833 shares worth $720K. The position accounts for ﹤0.01% of the portfolio, ranked #5437.

Morgan Stanley first reported a position in ELTX in Q1 2021 and has held it in 23 quarters since. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Morgan Stanley held 395,833 shares of Elicio Therapeutics worth $720K as of Q3 2026.
  • Morgan Stanley bought 370,287 Elicio Therapeutics shares in Q3 2026, an estimated $1.03M.
  • Elicio Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #5437 holding.
  • Morgan Stanley first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • 57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.